Neglected Tropical Diseases Diagnosis Market
Report ID: SQMIG35B2369
Report ID: SQMIG35B2369
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35B2369 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
130
|Figures:
77
Global Neglected Tropical Diseases Diagnosis Market size was valued at USD 6.4 Billion in 2024 and is poised to grow from USD 6.77 Billion in 2025 to USD 10.61 Billion by 2033, growing at a CAGR of 5.78% during the forecast period (2026-2033).
Neglected tropical diseases diagnosis industry refers to the ecosystem of technologies and service pathways used to detect infections such as leishmaniasis, Chagas, lymphatic filariasis and schistosomiasis, and this is significant because accurate identification underpins treatment, surveillance and elimination strategies. The primary driver is heightened global recognition and dedicated funding from multilateral organizations and philanthropic bodies, which transformed a historically neglected field into an active market.
Over the past two decades this attention catalyzed adoption of rapid diagnostic tests for field use, expansion of molecular platforms in regional labs, and public private collaborations exemplified by WHO roadmaps and Gates-funded pilot projects. When loop-mediated isothermal amplification and compact PCR devices are deployed they enable same-day confirmation of infections, which shortens time-to-treatment and improves patient outcomes while reducing inappropriate mass treatments. Similarly, integration of smartphone readers and cloud reporting turns individual test results into actionable surveillance data, which persuades funders to invest and encourages local manufacturers to scale production for endemic-country markets, and strengthens health systems.
How is AI improving diagnostic accuracy in the neglected tropical diseases market?
By integrating automated picture analysis with defined workflows that minimize human variability, Artificial Intelligence is increasing the diagnostic accuracy of neglected tropical illnesses. AI-driven parasite egg identification, onboard quality checks, and cloud-enabled data gathering that relieves staff of tedious work are important features. The current situation demonstrates a transition from strictly manual microscopy to AI-assisted systems that more accurately identify low-intensity diseases. The market setting promotes scalable, reasonably priced instruments because endemic locations have limited specialized capacity and expanding surveillance needs.
In March 2026, Enaiblers AB released field results for an AI digital pathology platform that facilitated scalable diagnoses, enhanced the detection of STH and Schistosoma mansoni eggs, and simplified reporting.
Market snapshot - (2026-2033)
Global Market Size
USD 6.4 Billion
Largest Segment
Immunodiagnostics
Fastest Growth
Molecular Diagnostics
Growth Rate
5.78% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global neglected tropical diseases diagnosis market is segmented by type, disease type, technology, end user and region. Based on type, the market is segmented into Molecular Diagnostics, Immunodiagnostics, Microscopy-Based Diagnostics, Culture-Based Diagnostics and Others. Based on disease type, the market is segmented into Dengue, Malaria, Leishmaniasis, Chagas Disease, Human African Trypanosomiasis (Sleeping Sickness), Schistosomiasis, Lymphatic Filariasis, Onchocerciasis, Soil-Transmitted Helminth Infections and Others. Based on technology, the market is segmented into Point-of-Care (POC) Testing, Laboratory-Based Testing, Digital Diagnostics & AI-Assisted Diagnostics and Others. Based on end user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, Public Health Programs, NGOs & International Health Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Molecular diagnostics segment dominates with large neglected tropical diseases diagnosis market share because its high analytical sensitivity and specificity transform detection of low density infections and complex coinfections, enabling reliable diagnosis where conventional methods fail. Their capacity for multiplex assays and genetic characterization supports treatment selection, resistance monitoring, and surveillance, which attracts sustained investment and laboratory adoption. Integration with automated platforms and standardized workflows reduces operator variability, driving clinical trust and programmatic uptake across care pathways.
As per neglected tropical diseases diagnosis market outlook, immunodiagnostics is emerging as the most rapidly expanding area due to scalable rapid tests and improved antigen designs that enable decentralized screening during mass campaigns. Manufacturer focus on low cost and easy to use formats and clearer regulatory pathways accelerates field deployment, expanding diagnostic reach and creating opportunities for integrated disease control efforts.
As per neglected tropical diseases diagnosis market analysis, point of care testing segment dominates because its rapid near patient results enable timely treatment decisions and large scale screening in settings with constrained laboratory access, bridging diagnostic gaps across care levels. Portable formats and simplified workflows reduce reliance on centralized infrastructure, prompting adoption by programs and NGOs. Combined with affordable consumables and targeted training, these tests drive widespread case detection and support control and elimination strategies.
As per neglected tropical diseases diagnosis market forecast, digital diagnostics and AI assisted diagnostics is emerging as the most rapidly expanding area because validated algorithms, smartphone microscopy, and cloud connectivity improve remote interpretation and quality assurance. Tech partnerships and investment accelerate deployment, automating workflows and enabling scalable surveillance and decision support, which expands diagnostic reach and program efficiency.
To get detailed segments analysis, Request a Free Sample Report
As per neglected tropical diseases diagnosis market regional outlook, through a combination of focused research ecosystems, concentrated industrial capability, and broad cooperation between the public and private sectors, Asia Pacific dominates the market. Regional businesses concentrate on developing point-of-care systems appropriate for diverse clinical settings and producing scalable assays. International quality standards are becoming more closely aligned with national regulatory systems, which promotes credibility and market access. Validation and clinical use of new diagnostics are accelerated by robust academic clusters and translational research initiatives. Local manufacturers and global corporations can extend distribution networks and promote knowledge transfer through strategic collaborations. Sustained regional leadership in diagnostic innovation and supply is supported by health system activities that prioritize surveillance and diagnostic readiness as well as advanced public procurement strategies.
As per neglected tropical diseases diagnosis market regional forecast, Japan is shaped by advanced biomedical research, strong regulatory frameworks, and high standards for diagnostic quality. Collaboration between academic institutions and industry drives innovation in assay development and validation. Manufacturers support production and distribution capacity while public health initiatives promote diagnostic preparedness. Clinical laboratory networks and hospital systems facilitate integration of new technologies, and international partnerships enhance knowledge exchange and access to diagnostic tools.
As per neglected tropical diseases diagnosis industry analysis, South Korea benefits from rapid technology adoption, strong manufacturing ecosystems, and a focus on precision diagnostics. Public and private research institutions collaborate to translate innovations into viable assays. Regulatory clarity and quality assurance frameworks support market entry and clinical implementation. Hospital laboratories and specialized diagnostic firms promote uptake, while international collaborations and export-oriented production amplify regional availability and integration of cutting edge diagnostic platforms.
North America is growing quickly because to a combination of infrastructure, innovation, and favorable reimbursement and regulatory frameworks. While agile startups and competitive diagnostics firms speed up product development and commercialization, deep clinical research capacity and well-established laboratory networks enable quick validation and clinical rollout of innovative tests. Molecular and point-of-care technology integration and diagnostic readiness are given top priority in robust public health systems and surveillance programs. Translation from research to everyday application is streamlined by collaborative ecosystems that connect academics, business, and healthcare providers. Furthermore, North America is positioned as a key exporter and adopter of cutting-edge diagnostic solutions for neglected tropical diseases due to its strong international distribution channels and mature supply chain capabilities.
United States benefits from advanced laboratory infrastructure, clinical research expertise, and collaboration between public health agencies and industry. Regulatory and accreditation frameworks facilitate validation and clinical use of novel assays. Established diagnostic companies and agile startups focus on molecular and point of care platforms, while hospital systems and reference laboratories drive adoption. International partnerships and commercial channels sustain technology transfer and global reach.
Canada features robust public health infrastructure, integrated laboratory networks, and emphasis on quality assurance, interoperability, and resilience. Collaborative research links universities, public laboratories and industry to adapt diagnostic technologies for varied clinical contexts. Government procurement and policy frameworks promote standardization and equitable access, while specialized diagnostic firms focus on scalable platforms. Cross border cooperation with international partners strengthens broader capacity and supports knowledge exchange.
Through coordinated research networks, regulatory consistency, and a focus on high quality standards, Europe is solidifying its position in the market for diagnosing neglected tropical illnesses. Strict validation and standardization of diagnostic tests are supported by pan-regional cooperation between academic institutions, reference labs, and business. The creation of advanced molecular and multiplex platforms appropriate for various therapeutic contexts is encouraged by investments in translational research and technology hubs. Standardized adoption and fair access across markets are promoted by public procurement tactics and the involvement of health authorities. Furthermore, European companies may successfully compete in global supply chains thanks to their robust manufacturing quality standards and experience in global health alliances. Europe is positioned as a trustworthy source of verified diagnoses and implementation experience thanks to cross-border clinical collaborations and knowledge sharing.
Germany benefits from a strong diagnostics industry, rigorous laboratory accreditation, and collaboration between research institutes and clinical centers. Emphasis on quality systems and regulatory compliance supports development and validation of sophisticated assays. Diagnostic manufacturers and clinical laboratories implement molecular and multiplex platforms in hospital networks. International engagement and export capacity extend reach, while public health programs support surveillance and diagnostic integration across care pathways.
United Kingdom is supported by academic medical centers, centralized reference laboratories, and public health agencies prioritizing diagnostic preparedness. Collaboration among universities, hospital laboratories, and industry accelerates assay development and validation. Regulatory compliance and quality assurance enable adoption of molecular and point of care platforms. International health partnerships and strong life sciences sector strengthen capacity to supply validated diagnostics for domestic use and global programs.
France leverages strong public research institutions, specialized reference laboratories, and medical technology industry. Collaborative programs between universities, hospitals, and diagnostics firms support rigorous clinical validation and quality assay development. National public health initiatives foster surveillance capacity and integration of molecular and point of care diagnostics into care pathways. Export expertise and international partnerships enhance distribution and implementation of validated diagnostic solutions across healthcare environments.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increased Public Health Funding
Advances In Diagnostic Technologies
Limited Healthcare Infrastructure
Regulatory and Reimbursement Challenges
Request Free Customization of this report to help us to meet your business objectives.
The neglected tropical diseases diagnosis market is characterized by a mix of global diagnostic companies, specialized infectious disease testing providers, and organizations focused on developing affordable point-of-care solutions for resource-limited settings. Key players are emphasizing the development of rapid diagnostic tests (RDTs), molecular diagnostics, immunoassays, and portable testing platforms to improve early detection of diseases such as dengue, leishmaniasis, Chagas disease, lymphatic filariasis, schistosomiasis, and human African trypanosomiasis.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the neglected tropical diseases diagnosis market growth is being propelled by increased public health funding that supports procurement, training and surveillance programs, while constrained healthcare infrastructure in many endemic areas remains a key restraint limiting routine deployment and scale-up. Molecular diagnostics currently lead the market due to their sensitivity for low-density and complex infections, and Asia Pacific is the dominant region due to strong manufacturing, research ecosystems and public–private collaboration. A secondary driver is rapid advances in diagnostic technologies, including portable molecular platforms and AI-enabled digital tools that expand point-of-care access and surveillance capacity, creating opportunities for scalable, programmatic impact.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 6.4 Billion |
| Market size value in 2033 | USD 10.61 Billion |
| Growth Rate | 5.78% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Neglected Tropical Diseases Diagnosis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Neglected Tropical Diseases Diagnosis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Neglected Tropical Diseases Diagnosis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Neglected Tropical Diseases Diagnosis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Neglected Tropical Diseases Diagnosis Market size was valued at USD 6.4 Billion in 2024 and is poised to grow from USD 6.77 Billion in 2025 to USD 10.61 Billion by 2033, growing at a CAGR of 5.78% during the forecast period (2026-2033).
I can do this but I need one quick clarification: are you willing to accept startups that started as academic or research spinouts before 2019 but launched NTD diagnostic products or received major NTD-focused grants after 2019, or must every startup be formally established in 2019 or later? 'Abbott Laboratories', 'F. Hoffmann-La Roche Ltd.', 'Siemens Healthineers AG', 'Danaher Corporation', 'Thermo Fisher Scientific Inc.', 'Bio-Rad Laboratories, Inc.', 'QIAGEN N.V.', 'Becton, Dickinson and Company', 'bioMérieux SA', 'Sysmex Corporation', 'Hologic, Inc.', 'PerkinElmer, Inc.', 'Agilent Technologies, Inc.', 'Mindray Medical International Limited', 'Trinity Biotech plc', 'Chembio Diagnostics, Inc.', 'OraSure Technologies, Inc.', 'Sekisui Diagnostics LLC', 'Arkray, Inc.', 'Fujirebio Holdings, Inc.'
Increased allocation of public health funding enables expanded diagnostic programs, procurement of modern tests, and support for distribution to underserved regions, thereby facilitating higher adoption of neglected tropical disease diagnostics. Governments and aid agencies can underwrite training for health workers, strengthen laboratory infrastructure, and subsidize point of care tools, which reduces barriers to diagnosis. This sustained financial backing fosters programmatic consistency, encourages manufacturers to scale production and innovate for local needs, and supports outreach strategies that make diagnostics more accessible to vulnerable populations, directly promoting market expansion.
Public-Private Partnerships: Collaborations between governments, non profit organizations, academic institutions and commercial diagnostics developers are accelerating innovation, pooling resources and aligning priorities to develop contextappropriate tests and distribution models. These partnerships emphasize capacity building, knowledge transfer and sustainable procurement pathways, enabling tailored diagnostic solutions that reflect local epidemiology and health system needs. The cooperative models support scale up of validated tools, strengthen laboratory networks and promote shared risk for product development, increasing the likelihood that affordable diagnostics reach underserved and marginalized populations.
Why does Asia Pacific Dominate the Global Neglected Tropical Diseases Diagnosis Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
